TOM SCHOENHERR
CEO, AMBRY GENETICS
WHY: Tapped to oversee Orange County’s third-largest medical diagnostics and testing company following its $1B sale in 2017 to Tokyo-based Konica Minolta Inc., promoted to CEO in 2021.
IN THE NEWS: Chosen to take part in three-year research project to find the genetic cause of rare diseases in pediatric patients, funded by the National Institutes of Health.
NOTABLE: Expects company to grow revenue by 25% this year ahead of two new product launches.
QUOTABLE: “This is going to bring answers to families who have been searching for quite some time.”
